跳至主要内容
临床试验/NCT03995563
NCT03995563Unknown4 期

The Effect of Epidural Steroid Use on Pain Relief in Patients With Continuous Epidural Nerve Block in Postherpetic Neuralgia Patients.

Korea University Guro Hospital1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2019年5月15日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
入组人数
40
试验地点
1
主要终点
VAS score

研究概览

简要总结

The efficiency of epidural steroid injection in patients who has postherpetic neuralgia is well known. In this study, the purpose is whether the continous epidural steroid injection is effective or not.

详细描述

Continous epidural injection will be done during 10 days. D group will be injected a 0.19% ropivacaine 8mL and dexametasone 1mg every other day during 10 days.

Continous epidural injection will be done during 10 days N group will be injected a 0.19% ropivacaine 8mL only every other day during 10 days

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients who has herpes zoster
  • Patients has a period (at least 1month) after onset of herpes zoster
  • Patients has a definite symptom along dermatome
  • ASA class I - II
  • Age : 18 - 80 years

排除标准

  • Patients who has a cancer
  • Patients who has a neurologic, psychologic, renal, hepatic and hematologic disease
  • Patients who has a other dermatologic disease
  • Patients who has major operation & procedure history
  • Patients who has a other pain origin
  • Patients who can not be inserted epidural catheter

研究组 & 干预措施

D group

Active Comparator

0.19% Ropivacaine 8mL + Dexametasone 1mg every other day injection during 10 days

干预措施: Dexamethasone (Drug)

D group

Active Comparator

0.19% Ropivacaine 8mL + Dexametasone 1mg every other day injection during 10 days

干预措施: Ropivacaine (Drug)

N group

Placebo Comparator

0.19% Ropivacaine 8mL only every other day injection during 10 days

干预措施: Ropivacaine (Drug)

结局指标

主要结局

VAS score

时间窗: up to 10 days

The investigator set the primary outcome If there is a 50% reduction of VAS score.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jung Eun Kim

Assistant professor

Korea University Guro Hospital

研究点 (1)

Loading locations...

相似试验